Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Transform Deadly Cancer into a Chronic and Eventually Curable Disease
Load image
Background image
About Us
About Us
Company Overview
We are a global clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies for patients across the spectrum of tumor types, with our multi-national R&D centers in both China and the United States. We have assembled a best-in-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.
Clinical Pipeline
Clinical Pipeline
R&D Platform
R&D Platform
Global Talent
Global Talent
View More
Background image Background image
Competitive Pipeline
Leveraging collaborations and internal discoveries, we have identified seven drug candidates and developed a robust pipeline of product candidates. Currently, our pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as four preclinical candidates.
View More
Background image Background image
Background image Background image Development Platform Development Platform
Research and Development
Platform
Led by a world-class executive and core R&D team, we have built our unique immuno-oncology platforms. Our innovation team is well positioned to establish ourselves as a leading global presence in the oncology market.
View More
Media
View More